An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Eribulin (Primary) ; Eribulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 10 Jan 2019 Planned number of patients changed from 73 to 103.
- 30 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
- 10 Oct 2018 Planned number of patients changed from 63 to 73.